Showing 2891-2900 of 5621 results for "".
- MeiraGTx Announces AAV-RPGR Granted Fast Track Designation by FDA for Treatment of X-Linked Retinitis Pigmentosa Due to RPGR Deficiencyhttps://modernod.com/news/meiragtx-announces-aav-rpgr-granted-fast-track-designation-by-fda-for-treatment-of-x-linked-retinitis-pigmentosa-due-to-rpgr-deficiency/2480212/MeiraGTx Limited, a clinical stage gene therapy company, announced that the FDA has granted Fast Track designation for AAV-RPGR for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase regulator (RPGR) gene. “XLRP is a devastating c
- Akorn Asks Delaware Court to Require Fresenius Kabi to Fulfill Its Obligations Under Merger Agreementhttps://modernod.com/news/akorn-asks-delaware-court-to-require-fresenius-kabi-to-fulfill-its-obligations-under-merger-agreement/2480214/Akorn filed a complaint in Delaware Chancery Court asking that Fresenius Kabi AG be required to fulfill its obligations under the definitive merger agreement, and issued the following statement: “Fresenius’ attempt to terminate the transaction on the pretext that the findings from the ongo
- Camras Vision Announces Completion of $5.7 Million Financing for Novel Glaucoma Devicehttps://modernod.com/news/camras-vision-announces-completion-of-5-7-million-financing-for-novel-glaucoma-device/2480215/Camras Vision has closed on $5.7 million in equity funding to be used to support four clinical trials globally, including a pilot study in the United States, to study the efficacy of the Camras device for the treatment of refractory glaucoma. The funding was made in its
- EyePoint Pharmaceuticals’ Yutiq for Posterior Segment Uveitis to be Presented at the 2018 ARVO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-yutiq-for-posterior-segment-uveitis-to-be-presented-at-the-2018-arvo-annual-meeting/2480232/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the Association for Research in Vision and Ophtha
- GlobalData: AI-Based Diabetic Retinopathy Device Can Reduce Burden on US Healthcare Systemhttps://modernod.com/news/globaldata-ai-based-diabetic-retinopathy-device-can-reduce-burden-on-us-healthcare-system/2480234/Iowa-based artificial intelligence (AI) diagnostics company IDx recently received market approval from the FDA for its AI-based medical device, IDx-DR, to detect greater than a mild level of diabetic retinopathy in adults. As the first of its kind to be authorized for commercialization, IDx-DR ha
- Alcon Introduces Preloaded Delivery System for the CyPass Micro-Stenthttps://modernod.com/news/alcon-introduces-preloaded-delivery-system-for-the-cypass-micro-stent/2480245/Alcon has announced the launch of the CyPass Ultra System designed to streamline the process of loading the CyPass Micro-Stent, a microinvasive glaucoma surgery (MIGS) device indicated for use in adult patients with mild-to-moderate primary open-angle glaucoma undergoing cataract surgery. The new
- Allergan Announces Official Launch of the TrueTear Intranasal Neurostimulation Devicehttps://modernod.com/news/allergan-announces-launch-of-the-truetear-intranasal-neurostimulation-device-at-ascrs/2480250/Allergan announced the official launch of TrueTear, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients. TrueTear, a handheld neurostimulation device with disposable tips that is inserted into the nasal cavity to
- EyePoint Pharmaceuticals Strengthens Global IP With Notices of Allowance for Two U.S. Patents Related to Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-strengthens-global-ip-with-notices-of-allowance-for-two-u-s-patents-related-to-dexycu/2480252/EyePoint Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued Notices of Allowance for two patents covering Dexycu, the company’s FDA-approved long-acting intraocular product for the treatment of postoperative inflammation. The first patent (U.S. patent ap
- FDA Approves Marketing For First AI Device for Diabetic Retinopathy Detectionhttps://modernod.com/news/fda-permits-marketing-of-ai-based-device-to-detect-certain-diabetes-related-eye-problems/2480256/The FDA has permitted marketing for the first medical device to use artificial intelligence to detect greater than a mild level of diabetic retinopathy in adults who have diabetes. The device, called IDx-DR, is a software program that uses an artificial intelligence algorithm to analyze im
- Veteran Business Development Executive Joins Lions Eye Institute as CMOhttps://modernod.com/news/veteran-business-development-executive-joins-lions-eye-institute-as-cmo/2480260/The Lions Eye Institute for Transplant & Research has announced the hiring of its first Chief Marketing Officer, Art Kurz, to strengthen the organization’s business development activities. Mr. Kurz, a former U.S. Air Force medic and graduate of Towson University, comes to Lions Eye Ins